What is GILD's current stock price?

As of now, GILD is trading at $120.94, with a daily change of +0.17%.

What are the risks associated with GILD stock?

GILD Key risk is its Low Risk Level, .

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Earnings Calendar Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

GILD Stock Analysis & IQ Rating | Gilead Sciences

GILD

Gilead Sciences

$120.94

+$0.20 | +0.17%

Create Alerts

Overview

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Headlines

52W High

$ 124.61

MKT CAP

$ 150.06B

52W Low

$ 86.08

VOL

$ 4.02M

P/E Ratio

24.19

AVG VOL

$ 7.55M

RSI

60.11

TREND

Uptrend

alert Latest Updates

StocksRunner 03:38 AM

Futures drifted slightly higher Thursday night ahead of Friday's September CPI report. The data was postponed from October 15 due to the government shutdown and now lands in an awkward spot where employment numbers have become more important for the Fed's next move. Still, this i...

GILD Stock IQ

Login to see Gilead Sciences (GILD) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

GILD Target Price

Login to display

Strengths

GILD Rewards

Earnings are forecast to grow

GILD Rewards

Upgraded on attractively valued

GILD Rewards

Trading below its fair value

GILD Rewards

Expands stock buyback program

Chart

$112.1 (+7.89%)

$115.38 (+4.82%)

$109.33 (+10.62%)

$91.69 (+31.90%)

1year

6month

3month

1month

GILD Risk Level

GILD has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

LOW

HIGH

GILD Analysts Opinion

GILD overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

GILD Analysts Opinion

GILD Analysts opinion is positive and also has improved from the past 3 months

GILD Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

82%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

67%

100%

GILD Street Opinion

GILD Street view is extremely bullish and have positive views on the near-term outlook

GILD Performance Sentiment

Sentiments overview associated with GILD events and the stock performance.

82%

12%

Positive

Negative

14 out of 17
events present

2 out of 17
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$120.31

Resistance
Price

$110.56

Current Price Range

$124.08

Show methods +

Linked to GILD

IQ

Close Price

Change

CGEN

3.50

1.80

+7.78%

AGEN

3.50

4.16

-0.96%

GILD Latest Analysis +

TD Cowen Maintains Gilead Sciences (GILD) Buy Recommendation. Fintel reports that on October 23 2025 TD Cowen maintained coverage of Gilead Sciences (NasdaqGS:GILD) with a Buy recommendation. Analyst Price Forecast Suggests 6.05% Upside

Today

$120.94 | +0.17%

Rating

Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?. Gilead (GILD) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Thu Oct 23, 2025

$120.74 | -0.59%

Earnings

Potential

CVS reportedly cites pricing concerns in excluding coverage for Gileads new HIV drug.

Wed Oct 22, 2025

$121.46 | -2.11%

Activity

Gileads Lyvdelzi Receives Health Canada Approval For Primary Biliary Cholangitis . (RTTNews) - Gilead Sciences Inc. (GILD) on Tuesday announced that Health Canada has approved Lyvdelzi for the treatment of adults with primary biliary cholangitis (PBC) a rare chronic autoimmune liver disease that gradually destroys the livers bile ducts.

Tue Oct 21, 2025

$124.08 | +0.79%

Activity

Gilead Coinbase Rocket Lab And A Tech Stock On CNBCs Final Trades. On CNBC'.s “.Halftime Report Final Trades”. GILD) as his final trade.Lending support to his choice Citigroup analyst Geoff Meacham maintained a Buy rating for Gilead Sciences on Oct. 8 raising the price target from $125 to $135.RKLB) has a 30% year-over-year earnings growth.Rocket Lab announced on Oct. 10 that it has signed a direct contract for two dedicated Electron launches with the Japan ...

Mon Oct 13, 2025

$118.21 | +0.88%

Activity

Rating

Citigroup Maintains Gilead Sciences (GILD) Buy Recommendation. Fintel reports that on October 8 2025 Citigroup maintained coverage of Gilead Sciences (NasdaqGS:GILD) with a Buy recommendation. Analyst Price Forecast Suggests 8.30% Upside

Thu Oct 9, 2025

$116.74 | -1.28%

Rating

Breaking Down Gilead Sciences: 6 Analysts Share Their Views. Providing a diverse range of perspectives from ish to bearish 6 analysts have published ratings on Gilead Sciences (NASDAQ:GILD) in the last three months.The table below offers a condensed view of their recent ratings showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.3120010000010000000020200Providing deeper insights analysts have established 12-month price targets indicating an average

Wed Oct 8, 2025

$118.25 | +1.26%

Momentum

Gilead Resolves Patent Litigations for HIV Treatment Biktarvy . Gileads settlement on Biktarvy patents delays generic entry until 2036 boosting investor confidence.

Tue Oct 7, 2025

$116.62 | +2.82%

Activity

Gilead Reaches Settlement To Block Biktarvy Generics Until 2036. GILD) on Monday entered into settlement agreements to resolve the patent litigations with GILD stock is showing positive momentum. Under the agreements no generic entry is expected April 1 2036 in the United States for Biktarvy tablets containing bictegravir (50 mg) emtricitabine (200 mg) and tenofovir alafenamide (25 mg).

Mon Oct 6, 2025

$113.58 | +0.79%

Activity

Momentum

Gilead Scores A Solid Win For Its Biggest Moneymaker. Shares Jump.

Mon Oct 6, 2025

$113.58 | +0.79%

Momentum

FAQ About GILD Stock Insights

What is GILD current stock price?

What are GILD stock strengths?

What risks are associated with GILD stock?

When is GILD next earnings report?

What is GILD market cap and volume?

What is GILD's current Stock IQ?

Should I buy GILD stock right now?

Is GILD a Strong Buy right now?

What does a 'Strong Buy' rating mean for GILD?

What does a 'Strong Sell' rating mean for GILD?

What factors influence GILD's Stock IQ?

Explore our GILD Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored GILD Stock Strategies
Effective Risk Management

FIND US ON

Receive our GILD Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

GILD

Gilead Sciences

Current Price

$120.94

+$0.20 | +0.17%

52W High

$ 124.61

MKT CAP

$ 150.06B

52W Low

$ 86.08

VOL

$ 4.02M

P/E Ratio

24.19

AVG VOL

$ 7.55M

RSI

60.11

TREND

Uptrend

Create Alerts

Overview

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

GILD Rewards

Earnings are forecast to grow

GILD Rewards

Upgraded on attractively valued

GILD Rewards

Trading below its fair value

GILD Rewards

Expands stock buyback program

Linked to GILD

Symbol

IQ

Close

Change

CGEN

3.50

1.80

+7.78%

AGEN

3.50

4.16

-0.96%

GILD Stock IQ

Login to unlock Gilead Sciences (GILD) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Chart

$112.1 (+7.89%)

$115.38 (+4.82%)

$109.33 (+10.62%)

$91.69 (+31.90%)

1year

6month

3month

1month

GILD Analysts Opinion

GILD Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

GILD Analysts Opinion

GILD Analysts opinion is positive and also has improved from the past 3 months

GILD Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

82%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

67%

100%

GILD Street Opinion

GILD Street view is extremely bullish and have positive views on the near-term outlook

GILD Risk Level

GILD has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

LOW

HIGH

GILD Performance Sentiment

Sentiments overview associated with GILD events and the stock performance.

82%

12%

Positive

Negative

14 out of 17
events present

2 out of 17
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$120.31

Resistance
Price

$110.56

Current Price Range

$124.08

Show methods +

GILD Latest Analysis

StocksRunner 03:38 AM

Futures drifted slightly higher Thursday night ahead of Friday's September CPI report. The data was postponed from October 15 due to the government shutdown and now lands in an awkward spot where employment numbers have become more important for the Fed's next move. Still, this i...

TD Cowen Maintains Gilead Sciences (GILD) Buy Recommendation. Fintel reports that on October 23 2025 TD Cowen maintained coverage of Gilead Sciences (NasdaqGS:GILD) with a Buy recommendation. Analyst Price Forecast Suggests 6.05% Upside

Today

$120.94 | +0.17%

Rating

Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?. Gilead (GILD) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Thu Oct 23, 2025

$120.74 | -0.59%

Earnings

Potential

CVS reportedly cites pricing concerns in excluding coverage for Gileads new HIV drug.

Wed Oct 22, 2025

$121.46 | -2.11%

Activity

Gileads Lyvdelzi Receives Health Canada Approval For Primary Biliary Cholangitis . (RTTNews) - Gilead Sciences Inc. (GILD) on Tuesday announced that Health Canada has approved Lyvdelzi for the treatment of adults with primary biliary cholangitis (PBC) a rare chronic autoimmune liver disease that gradually destroys the livers bile ducts.

Tue Oct 21, 2025

$124.08 | +0.79%

Activity

Gilead Coinbase Rocket Lab And A Tech Stock On CNBCs Final Trades. On CNBC'.s “.Halftime Report Final Trades”. GILD) as his final trade.Lending support to his choice Citigroup analyst Geoff Meacham maintained a Buy rating for Gilead Sciences on Oct. 8 raising the price target from $125 to $135.RKLB) has a 30% year-over-year earnings growth.Rocket Lab announced on Oct. 10 that it has signed a direct contract for two dedicated Electron launches with the Japan ...

Mon Oct 13, 2025

$118.21 | +0.88%

Activity

Rating

Citigroup Maintains Gilead Sciences (GILD) Buy Recommendation. Fintel reports that on October 8 2025 Citigroup maintained coverage of Gilead Sciences (NasdaqGS:GILD) with a Buy recommendation. Analyst Price Forecast Suggests 8.30% Upside

Thu Oct 9, 2025

$116.74 | -1.28%

Rating

Breaking Down Gilead Sciences: 6 Analysts Share Their Views. Providing a diverse range of perspectives from ish to bearish 6 analysts have published ratings on Gilead Sciences (NASDAQ:GILD) in the last three months.The table below offers a condensed view of their recent ratings showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.3120010000010000000020200Providing deeper insights analysts have established 12-month price targets indicating an average

Wed Oct 8, 2025

$118.25 | +1.26%

Momentum

Gilead Resolves Patent Litigations for HIV Treatment Biktarvy . Gileads settlement on Biktarvy patents delays generic entry until 2036 boosting investor confidence.

Tue Oct 7, 2025

$116.62 | +2.82%

Activity

Gilead Reaches Settlement To Block Biktarvy Generics Until 2036. GILD) on Monday entered into settlement agreements to resolve the patent litigations with GILD stock is showing positive momentum. Under the agreements no generic entry is expected April 1 2036 in the United States for Biktarvy tablets containing bictegravir (50 mg) emtricitabine (200 mg) and tenofovir alafenamide (25 mg).

Mon Oct 6, 2025

$113.58 | +0.79%

Activity

Momentum

Gilead Scores A Solid Win For Its Biggest Moneymaker. Shares Jump.

Mon Oct 6, 2025

$113.58 | +0.79%

Momentum

Discover GILD Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of GILD. We're here to help you make informed investment decisions today.

FIND US ON

Receive our GILD Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

GILD Stock trends

GILD Stock performance

GILD Stock analysis

GILD investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing GILD

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing GILD

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

GILD Stock Analysis & IQ Rating | Gilead Sciences

GILD Stock IQ

GILD Target Price

GILD Risk Level

GILD Analysts Opinion

GILD Street Consensus

GILD Performance Sentiment

Technical Price Levels

Explore our GILD Stock insights

Receive our GILD Daily Alerts

GILD Stock IQ

GILD Street Consensus

GILD Risk Level

Technical Price Levels

Discover GILD Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of GILD. We're here to help you make informed investment decisions today.

Receive our GILD Daily Alerts

GILD Runner Alarm